Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen

Japanese Journal of Clinical Oncology

Volumn 36, Issue 2, 2006, Pages 104-108

  Takahashi, Takeshi ^a   Higashi, Shin ^a   Nishiyama, Hiroyuki ^a   Segawa, Takeshiko ^a   Nakamura, Eijiro ^a   Kinoshita, Hidefumi ^a   Itoh, Noriyuki ^a   Yamamoto, Shingo ^a   Kamoto, Toshiyuki ^a   Habuchi, Tomonori ^a   Ogawa, Osamu ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Paclitaxel; Urothelial cancer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; METASTASIS; NEPHROTOXICITY; NEURALGIA; NEUTROPENIA; PERFORMANCE; SAMPLE SIZE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 33645157123     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi220     Document Type: Article

References (19)

1. Lehmann J, Retz M, Stockle M. Chemotherapy in the post-MVAC era: The case for adjuvant chemotherapy. World J Urol 2002;20:144.
2. de Wit R, Bellmunt J. Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol 2003;45:191.
3. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068.
4. Meluch AA, Greco FA, Burris HA III, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018.
5. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998;9:733.
6. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993.
7. Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: A prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 1998;28:497.
8. Frassoldati A, Federico M, Barbieri F, Brausi M, Pollastri C, Berri G, et al. Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer. Med Oncol Tumor Pharmacother 1991;8:99.
9. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004;22:393.
10. Lara PN Jr, Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, et al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer 2004;100:82.
11. Neri B, Doni L, Fulignati C, Gemelli MT, Turrini M, Di Cello V, et al. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: A phase II. Anticancer Res 2002;22:2981.
12. Ricci S, Galli L, Chioni A, Iannopollo M, Antonuzzo A, Francesca F, et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 2002;95:1444.
13. Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: A trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:2743.
14. Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study. Br J Cancer 2005;92: 645.
15. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003;98:1863.
16. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase I/II dose-escalating study. Eur J Cancer 2000;36:2329.
17. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13.
18. Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001;19:1071.
19. Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. J Clin Oncol 2005;23:1185.